We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Transformative New System Brings Whole Genome Sequencing to the Desktop

By LabMedica International staff writers
Posted on 30 Jan 2014
A new sequencer transforms high-throughput performance into an affordable desktop form factor, enabling users to perform applications more quickly and conveniently.

Illumina (San Diego, CA, USA) now adds the NextSeq 500 System to its next-generation sequencing (NGS) portfolio. More...
The NextSeq 500 System, currently priced at USD 250,000, delivers the flexible power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, effectively transforming a broad range of high-throughput applications into affordable, everyday research tools.

“Illumina’s sequencing portfolio is the most comprehensive in the world, and the addition of the NextSeq 500 System furthers this distinction by enabling next-generation sequencing to become an everyday tool,” said Jay Flatley, CEO, Illumina; “The NextSeq 500 was reimagined from the ground up and uses technology breakthroughs in optics, fluidics and chemistry to bring high throughput power to the desktop at a significantly reduced cost.”

Its push-button operation delivers a one-day turnaround for several sequencing applications, including one whole human genome and up to 16 exomes, up to 20 noninvasive prenatal testing samples, up to 20 transcriptomes, up to 48 gene expression samples and up to 96 targeted panels. With its streamlined informatics, sequencing data can be run through a range of open source or commercial pipelines, or instantly transferred, analyzed, and stored securely in "BaseSpace,” or in the new "BaseSpace OnSite" for researchers needing an on premises solution.

Users also have the flexibility to switch to lower throughput sequencing as needed, and while other platforms require several pieces of specialized equipment, the NextSeq 500 System integrates cluster generation and sequencing into a single instrument. Data is generated in as little as 12 hours for a 75-cycle sequencing run and less than 30 hours for paired 150-cycle reads. The new system is supported by the full suite of Illumina sample preparation and target enrichment solutions, offering library compatibility across the entire Illumina sequencing portfolio. Its configurable output supports a wide range of applications and sample sizes with the accuracy of Illumina sequencing-by-synthesis (SBS) technology.

Related Links:

Illumina



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.